Angela Dardano

Angela Dardano

Auto-generated profile, based on publicly available information

Angela Dardano

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2022 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
LNLorenzo Nesti
Lorenzo Nesti
NPNicola Riccardo Pugliese
Nicola Riccardo Pugliese
PSPaolo Sciuto
Paolo Sciuto
DTDomenico Trico
Domenico Trico
ADAngela Dardano
Angela Dardano
ANAndrea Natali
Andrea Natali
Background: The mechanism through which sodium-glucose cotransporter 2 inhibitors (SGLT2i) prevent the incidence of heart failure and/or affect cardiac structure and function remains unclear. Methods: The EMPA-HEART trial is aimed at verifying whether empagliflozin improves myocardial contractility (left ventricle global longitudinal strain, LV-GLS) and/or cardiopulmonary fitness (peak oxygen uptake, VO2peak) in subjects with type 2 diabetes (T2D) without heart disease. Patients with T2D, normal LV systolic function (2D-Echo EF > 50%), and no heart disease were randomized to either empagliflozin 10 mg or sitagliptin 100 mg for 6 months and underwent repeated cardiopulmonary exercise tests with echocardiography and determination of plasma biomarkers. Results: Forty-four patients completed the study, 22 per arm. Despite comparable glycaemic control, modest reductions in body weight (− 1.6; [− 2.7/− 0.5] kg, p = 0.03) and plasma uric acid (− 1.5; [− 2.3/− 0.6], p = 0.002), as well as an increase in haemoglobin (+ 0.7; [+ 0.2/+ 1.1] g/dL, p = 0.0003) were evident with empagliflozin. No difference was detectable in either LV-GLS at 1 month (empagliflozin vs sitagliptin: + 0.44; [− 0.10/+ 0.98]%, p = 0.11) and 6 months of therapy (+ 0.53; [− 0.56/+ 1.62]%), or in VO2peak (+ 0.43; [− 1.4/+ 2.3] mL/min/kg, p = 0.65). With empagliflozin, the subgroup with baseline LV-GLS below the median experienced a greater increase (time*drug p < 0.05) in LV-GLS at 1 month (+ 1.22; [+ 0.31/+ 2.13]%) and 6 months (+ 2.05; [+ 1.14/+ 2.96]%), while sitagliptin induced a modest improvement in LV-GLS only at 6 months (+ 0.92; [+ 0.21/+ 0.62]%). Conclusions: Empagliflozin has neutral impact on both LV-GLS and exercise tolerance in subjects with T2D and normal left ventricular function. However, in patients with subclinical dysfunction (LV-GLS < 16.5%) it produces a rapid and sustained amelioration of LV contractility. Trial registration EUDRACT Code 2016-002225-10

21 June 2022 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
ADAngela Dardano
Angela Dardano
GAGayane Aghakhanyan
Gayane Aghakhanyan
CMCarlo Moretto
Carlo Moretto
ACAnnamaria Ciccarone
Annamaria Ciccarone
RBRosario Bellini
Rosario Bellini
GDGiuseppe Daniele
Giuseppe Daniele

30 January 2010 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
MMMichelangelo Maestri
Michelangelo Maestri
Fabio MonzaniFabio Monzani
Fabio Monzani
EBEnrica Bonanni
Enrica Bonanni
ECElisa Di Coscio
Elisa Di Coscio
FCFabio Cignoni
Fabio Cignoni
LMLuigi Murri
Luigi Murri

1 September 2007 in European Journal of Endocrinology
Verified
Journal Article
Open access
ADAngela Dardano
Angela Dardano
Fabio MonzaniFabio Monzani
Fabio Monzani
We read with interest the review article by Duntas &\ud Biondi dealing with clinical and quality of life\ud consequences induced by short-term hypothyroidism\ud (1). Withdrawal of levothyroxine therapy exacerbates\ud neuropsychiatric symptoms and increases cardiovascular\ud risk, although these effects are usually reversible\ud restoring a condition of stable euthyroidism (1). Shortterm\ud hypothyroidism is associated with cardiac abnormalities,\ud increased peripheral vascular resistance, and\ud endothelium dysfunction. In this setting, the recent use\ud of recombinant human thyrotropin (rhTSH) in the\ud clinical practice of thyroid carcinoma represents a valid\ud alternative to levothyroxine withdrawal. The authors\ud state that rhTSH administration is not accompanied by\ud significant cardiac alterations and induces beneficial\ud effects on the vascular system by increasing circulating\ud nitric oxide (2)

2 March 2026 in BMJ Open
Verified
Journal Article
Open access
ADAngela Dardano
Angela Dardano
GDGiuseppe Daniele
Giuseppe Daniele
CGChristian Göbl
Christian Göbl
Andrea TuraAndrea Tura
Andrea Tura
Introduction: Sarcopenia is characterised by loss of muscle mass and strength. Although ageing is the most likely risk factor of sarcopenia, sarcopenia is prevalent even in non-elderly people. Type 2 diabetes (T2D) is a risk factor for sarcopenia, as T2D shares with sarcopenia several aetiological factors. Meanwhile, gestational diabetes mellitus (GDM) is characterised by metabolic alterations that resemble those observed in T2D, including increased insulin resistance (present even in physiologic pregnancies). Hence, GDM presents two major risk factors for sarcopenia, that is, dysglycaemia and insulin resistance. Moreover, the number of pregnancies at age >40 years is increasing, which is in an age range in which sarcopenia prevalence is already not negligible. However, data on the prevalence of sarcopenia prevalence in GDM and its effect on pregnancy outcomes are limited. Thus, this study aims to evaluate the prevalence of sarcopenia in women with GDM (and in pregnant women without GDM), identify risk factors and determine its effect on delivery and maternal and fetal outcomes. Methods and analysis: For this study, 100 each of women with and without GDM will be recruited. Women will undergo an oral glucose tolerance test within weeks 24–28 for possible GDM diagnosis (in weeks 16–18 for high-risk women). Muscle/physical performance tests will be conducted at weeks 28–32 for possible diagnosis of sarcopenia/presarcopenia. Cognitive function will also be assessed. For all women, information regarding pregnancy progression, along with any complications, will be collected. Collected data will be analysed according to the main objectives of the study: (i) determine the prevalence of sarcopenia/presarcopenia in pregnancy with and without GDM, (ii) identify factors associated with sarcopenia risk, (iii) determine the effect of sarcopenia/presarcopenia on pregnancy outcomes, (iv) explore the relationship between sarcopenia and cognitive function. Therefore, this study will provide information on sarcopenia/presarcopenia prevalence in GDM and, possibly, in pregnancy not complicated by dysglycaemia. Furthermore, the study will provide knowledge on the main factors associated with sarcopenia/presarcopenia in GDM/pregnancy. The identification of such factors will be relevant for an initial guidance for treatments that may prevent sarcopenia in GDM/pregnant women. This will become of even greater interest if sarcopenia/presarcopenia influences pregnancy outcomes, especially in GDM women. Ethics and dissemination: The study protocol has been approved by the Comitato Etico Regione Toscana - Area Vasta Nord Ovest (CEAVNO) on 25 July 2024 and by the Local Ethics Committee of the Medical University of Vienna on 17 June 2024. Participants’ enrolment began in May 2025. The results of the study will be presented at national and international conferences and in peer-reviewed journals. Trial registration number: ClinicalTrials.gov Identifier: NCT06876090 ; Registration Date: 2025-03-14

23 April 2024 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
GDGiuseppe Daniele
Giuseppe Daniele
Andrea TuraAndrea Tura
Andrea Tura
ABAlex Brocchi
Alex Brocchi
ASAlessandro Saba
Alessandro Saba
BCBeatrice Campi
Beatrice Campi
SPStefano Del Prato
Stefano Del Prato
OBJECTIVE: To explore the complementary effects of a combination of dipeptidyl peptidase 4 and sodium–glucose cotransporter 2 inhibitors added to metformin on hormonal and metabolic responses to meal ingestion. RESEARCH DESIGN AND METHODS: Forty-five patients (age 58 ± 8 years; HbA1c 58 ± 6 mmol/mol; BMI 30.7 ± 3.2 kg/m2) with type 2 diabetes uncontrolled with metformin were evaluated at baseline and 3 and 28 days after 5 mg saxagliptin (SAXA), 10 mg dapagliflozin (DAPA), or 5 mg saxagliptin plus 10 mg dapagliflozin (SAXA+DAPA) using a mixed-meal tolerance test (MMTT) spiked with dual-tracer glucose to assess glucose metabolism, insulin secretion, and sensitivity. RESULTS: At day 3, fasting and mean MMTT glucose levels were lower with SAXA+DAPA (−31.1 ± 1.6 and −91.5 ± 12.4 mg/dL) than with SAXA (−7.1 ± 2.1 and −53 ± 10.5 mg/dL) or DAPA (−17.0 ± 1.1 and −42.6 ± 10.0 mg/dL, respectively; P < 0.001). Insulin secretion rate (SAXA+DAPA +75%; SAXA +11%; DAPA +3%) and insulin sensitivity (+2.2 ± 1.7, +0.4 ± 0.7, and +0.4 ± 0.4 mg ⋅ kg−1⋅ min−1, respectively) improved with SAXA+DAPA (P < 0.007). Mean glucagon-like peptide 1 (GLP-1) was higher with SAXA+DAPA than with SAXA or DAPA. Fasting glucagon increased with DAPA and SAXA+DAPA but not with SAXA. Fasting endogenous glucose production (EGP) increased with SAXA+DAPA and DAPA. During MMTT, EGP suppression was greater (48%) with SAXA+DAPA (vs. SAXA 44%; P = 0.02 or DAPA 34%; P = 0.2). Metabolic clearance rate of glucose (MCRglu) increased more with SAXA+DAPA. At week 4, insulin secretion rate, β-cell glucose sensitivity, and insulin sensitivity had further increased in the SAXA+DAPA group (P = 0.02), with no additional changes in GLP-1, glucagon, fasting or MMTT EGP, or MCRglu. CONCLUSIONS: SAXA+DAPA provided superior glycemic control compared with DAPA or SAXA, with improved β-cell function, insulin sensitivity, GLP-1 availability, and glucose clearance.